Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Clinically Relevant Response to Cisplatin-5-Fluorouracyl in Intestinal-Type Sinonasal Adenocarcinoma with Loss of Vision: A Case Report.

Claus J, Jorissen M, Vander Poorten V, Nuyts S, Hermans R, Casteels I, Clement PMJ.

Case Rep Oncol. 2019 Mar 29;12(1):277-281. doi: 10.1159/000499602. eCollection 2019 Jan-Apr.

2.

Interobserver variability in delineation of target volumes in head and neck cancer.

van der Veen J, Gulyban A, Nuyts S.

Radiother Oncol. 2019 Apr 29;137:9-15. doi: 10.1016/j.radonc.2019.04.006. [Epub ahead of print]

PMID:
31048235
3.

Bilateral radiation-induced squamous cell carcinomas of the external auditory canal 30 years after radiotherapy for a pituitary adenoma: a case report.

De Roeck L, Nuyts S.

Tumori. 2019 Feb 26:300891619832258. doi: 10.1177/0300891619832258. [Epub ahead of print]

PMID:
30808258
4.

Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches.

Deschuymer S, Mehanna H, Nuyts S.

Front Oncol. 2018 Oct 9;8:439. doi: 10.3389/fonc.2018.00439. eCollection 2018. Review.

5.

Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer.

Spaas M, Decallonne B, Laenen A, Billen J, Nuyts S.

Eur Thyroid J. 2018 Aug;7(4):211-217. doi: 10.1159/000489849. Epub 2018 Jun 26.

6.

Low-Level Laser Therapy Stimulates Proliferation in Head and Neck Squamous Cell Carcinoma Cells.

Bamps M, Dok R, Nuyts S.

Front Oncol. 2018 Aug 28;8:343. doi: 10.3389/fonc.2018.00343. eCollection 2018.

7.

Patient Selection in Human Papillomavirus Related Oropharyngeal Cancer: The Added Value of Prognostic Models in the New TNM 8th Edition Era.

Deschuymer S, Dok R, Laenen A, Hauben E, Nuyts S.

Front Oncol. 2018 Jul 23;8:273. doi: 10.3389/fonc.2018.00273. eCollection 2018.

8.

Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.

Michiels S, Poels K, Crijns W, Delombaerde L, De Roover R, Vanstraelen B, Haustermans K, Nuyts S, Depuydt T.

Radiother Oncol. 2018 Sep;128(3):479-484. doi: 10.1016/j.radonc.2018.04.021. Epub 2018 May 5.

PMID:
29739713
9.

Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer.

Deschuymer S, Nevens D, Duprez F, Laenen A, Dejaeger E, De Neve W, Goeleven A, Nuyts S.

Br J Radiol. 2018 Jul;91(1088):20180155. doi: 10.1259/bjr.20180155. Epub 2018 May 23.

PMID:
29668302
10.

In Regard to Bibault et al.

Daisne JF, Nuyts S, Duprez F, Bihin B.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):807-808. doi: 10.1016/j.ijrobp.2017.11.039. No abstract available.

PMID:
29413296
11.

Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.

Nevens D, Duprez F, Bonte K, Deron P, Huvenne W, Laenen A, De Neve W, Nuyts S.

Radiother Oncol. 2018 Mar;126(3):571-572. doi: 10.1016/j.radonc.2017.12.015. Epub 2018 Jan 4. No abstract available.

PMID:
29307729
12.

Does the total dysphagia risk score correlate with swallowing function examined by videofluoroscopy?

Nevens D, Goeleven A, Duprez F, Braeken R, Decabooter E, De Smet M, Lutters L, Dejaeger E, De Neve W, Nuyts S.

Br J Radiol. 2018 Feb;91(1083):20170714. doi: 10.1259/bjr.20170714. Epub 2018 Jan 2.

13.

Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

Glorieux M, Dok R, Nuyts S.

Oncotarget. 2017 Sep 16;8(46):81662-81678. doi: 10.18632/oncotarget.20953. eCollection 2017 Oct 6. Review.

14.

Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?

van der Veen J, Nuyts S.

Cancers (Basel). 2017 Oct 6;9(10). pii: E135. doi: 10.3390/cancers9100135. Review.

15.

Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?

Nevens D, Nuyts S.

Br J Radiol. 2017 Dec;90(1080):20170596. doi: 10.1259/bjr.20170596. Epub 2017 Oct 3.

16.

Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.

Michiels S, Barragán AM, Souris K, Poels K, Crijns W, Lee JA, Sterpin E, Nuyts S, Haustermans K, Depuydt T.

Radiother Oncol. 2018 Jul;128(1):161-166. doi: 10.1016/j.radonc.2017.09.006. Epub 2017 Sep 23.

PMID:
28951008
17.

The true value of altered fractionation in head and neck cancer.

Nuyts S.

Lancet Oncol. 2017 Sep;18(9):1147-1148. doi: 10.1016/S1470-2045(17)30568-5. Epub 2017 Jul 27. No abstract available.

PMID:
28757378
18.

Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.

Nevens D, Duprez F, Bonte K, Deron P, Huvenne W, Laenen A, De Neve W, Nuyts S.

Radiother Oncol. 2017 Aug;124(2):220-224. doi: 10.1016/j.radonc.2017.07.011. Epub 2017 Jul 26.

PMID:
28756006
19.

Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.

Nevens D, Duprez F, Daisne JF, De Neve W, Nuyts S.

Radiother Oncol. 2017 Aug;124(2):336. doi: 10.1016/j.radonc.2017.07.003. Epub 2017 Jul 24. No abstract available.

PMID:
28751230
20.

Dual role for p16 in the metastasis process of HPV positive head and neck cancers.

Dok R, Glorieux M, Holacka K, Bamps M, Nuyts S.

Mol Cancer. 2017 Jun 29;16(1):113. doi: 10.1186/s12943-017-0678-8.

Supplemental Content

Loading ...
Support Center